Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

RAPID AFib Decision Aid for Stroke Prevention in Atrial Fibrillation

Pilot Clinical Trial of the Risk Assessment and Personal Preference to Improve Decisions in Atrial Fibrillation Patient Decision Aid for Stroke Prevention in Atrial Fibrillation: the RAPID AFib Pilot Trial.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The goal of this pilot clinical trial is to evaluate the utility of a new electronic patient decision aid for stroke prevention therapy in patients with atrial fibrillation. The main questions it aims to answer are: Is the patient decision aid acceptable to both patients and physicians? Does the patient decision aid lead to more effective shared decision-making than standard care among patients with atrial fibrillation who are considering stroke prevention therapy? Participants with a recent diagnosis of atrial fibrillation will be enrolled before an upcoming specialist physician visit. Researchers will compare a pre-visit intervention consisting of standard educational materials plus use of the patient decision aid to educational materials alone to see if using the decision aid results in improved shared decision making during the clinic visit.

Who May Be Eligible (Plain English)

Who May Qualify: - Non-valvular AF diagnosed within 12 months, with any level of stroke risk assessed by CHA2DS2-VASc score. - Age 18 or older - Either no OAC treatment or treated for less than 90 days. - Initial specialist AF visit scheduled in 7-30 days. Who Should NOT Join This Trial: - Valvular AF, defined, per Canadian Cardiovascular Society Guidelines, as AF in the presence of mechanical heart valves, rheumatic mitral stenosis, or moderate to severe nonrheumatic mitral stenosis. - Currently prescribed dual antiplatelet therapy (ASA plus either clopidogrel, ticagrelor, or prasugrel) for an indication other than AF. - Has an independent, non-AF indication for oral anticoagulation. - Has a non-modifiable impediment to effective use of web-based tools. Examples include lack of internet access, lack of English literacy (Grade 5 level). Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Non-valvular AF diagnosed within 12 months, with any level of stroke risk assessed by CHA2DS2-VASc score. * Age 18 or older * Either no OAC treatment or treated for less than 90 days. * Initial specialist AF visit scheduled in 7-30 days. Exclusion Criteria: * Valvular AF, defined, per Canadian Cardiovascular Society Guidelines, as AF in the presence of mechanical heart valves, rheumatic mitral stenosis, or moderate to severe nonrheumatic mitral stenosis. * Currently prescribed dual antiplatelet therapy (ASA plus either clopidogrel, ticagrelor, or prasugrel) for an indication other than AF. * Has an independent, non-AF indication for oral anticoagulation. * Has a non-modifiable impediment to effective use of web-based tools. Examples include lack of internet access, lack of English literacy (Grade 5 level).

Treatments Being Tested

BEHAVIORAL

Electronic patient decision aid

Link to website with information about atrial fibrillation treatments, plus access to the web-based patient decision aid to enable shared decision making between patients and their physicians for atrial fibrillation stroke prevention treatments

OTHER

Information

Link to website with information about atrial fibrillation treatments

Locations (2)

Calgary Zone, Alberta Health Services
Calgary, Alberta, Canada
Vita Diagnostics
Calgary, Alberta, Canada